Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties

The ruling follows a patent dispute involving Guardant Health, with the judge ordering royalties after finding against the company. The headline does not provide the royalty amount, the patents involved, the products affected, or the timing of any payments.

The direct exposure is GH, whose FY 2025 revenue was $982.0M, up 32.9% YoY, according to SEC EDGAR data. That growth sits alongside a -42.4% net margin and dilutive EPS of $-3.32, leaving the company financially sensitive to additional obligations.

The next key disclosures are the size and duration of the royalty burden, any impact on product sales or licensing, and whether Guardant appeals the ruling. The market's initial reaction was negative, but the available reporting does not establish the judgment's dollar value or whether operations are materially constrained.